Greenwood Village, CO, United States
Greenwood Village, CO, United States

Time filter

Source Type

Patent
Ampio Pharmaceuticals | Date: 2015-12-02

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.


The present invention provides a method of modulating various aspects of the immune system. In particular, the present invention teaches the use of diketopiperazines (DKPs) to modulate various aspects of the immune system such as, for example, inflammation, T-cells and various cytokines.


Patent
Ampio Pharmaceuticals | Date: 2015-01-23

The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.


Patent
Ampio Pharmaceuticals | Date: 2015-08-18

The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin.


Patent
Ampio Pharmaceuticals | Date: 2016-04-27

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The method comprises administering an effective amount of a danazol compound to the animal accounting for the body fat content of the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal.


Patent
Ampio Pharmaceuticals | Date: 2014-08-08

The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R^(1 )and R^(2 )are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.


Patent
Ampio Pharmaceuticals | Date: 2014-08-27

The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation.


Patent
Ampio Pharmaceuticals | Date: 2015-03-03

The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides by either increasing or decreasing the content of diketopiperazines in the compositions and the resultant improved pharmaceutical compositions.


Patent
Ampio Pharmaceuticals | Date: 2015-07-06

The invention provides a method of treating a disease or condition mediated by vascular hyperpermeability in an animal. The method comprises administering an amount of a danazol compound effective to inhibit vascular hyperpermeability and an amount of a second drug effective to treat the disease or condition. The invention further provides a method of inhibiting vascular hyperpermeability when it is a side effect caused by administration of a drug to, or another treatment of, an animal. The method comprises administration of an amount of a danazol compound effective to inhibit the vascular hyperpermeability. The invention also provides a method of modulating the cytoskeleton of endothelial cells in an animal comprising administering an amount of a danazol compound and an amount of a second drug effective to modulate the cytoskeleton. The present invention also relates to pharmaceutical compositions and kits comprising a danazol compound and a second drug.


Patent
Ampio Pharmaceuticals | Date: 2014-11-05

The invention provides an effective amount of a diketopiperazine having the following formula for use in the treatment of a T-cell mediated autoimmune disease:R^(1) and R^(2), which may be the same or different, each is:(a) a side chain of an amino acid, wherein the amino acid is glycine, alanine, valine, norvaline, -aminoisobutyric acid, 2,4-diaminobutyric acid, 2,3-diaminobutyric acid, leucine, isoleucine, norleucine, serine, homoserine, threonine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, hydroxylysine, histidine, arginine, homoarginine, citrulline, phenylalanine, p-aminophenylalanine, tyrosine, thyroxine, cysteine, homocysteine, methionine, penicillamine or ornithine; provided, however, that when R^(1) is the side chain of asparagine or glutamine, then R^(2) cannot be the side chain of lysine or ornithine, and when R^(1) is the side chain of lysine or ornithine, then R^(2) cannot be the side chain of asparagine or glutamine;(b) a derivative of a side chain of an amino acid, wherein the amino acid is one of those recited in (a), and the derivatized side chain has:(i) an -NH_(2) group replaced by an -NHR^(3) or -N(R^(3))_(2) group, wherein each R^(3) may independently be a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;(ii) an -OH group replaced by an -O-PO_(3)H_(2) or -OR^(3) group, wherein each R^(3) may independently be a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;(iii) a -COOH group replaced by a -COOR^(3) group, wherein each R^(3) may independently be a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;(iv) a -COOH group replaced by a -CON(R^(4))_(2) group, wherein each R^(4) may independently be H or a substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, aryl, alkylaryl, arylalkyl or heteroaryl;(v) an -SH group replaced by -S-S-CH_(2)-CH(NH_(2))-COOH or -S-S-CH_(2)-CH_(2)-CH(NH_(2))-COOH;(vi) a -CH_(2)- group replaced by a -CH(NH_(2))- or a -CH(OH)- group;(vii) a -CH_(3) group replaced by a -CH_(2)-NH_(2) or a -CH_(2)-OH group; and/or(viii) an H which is attached to a carbon atom replaced by a halogen; ora physiologically-acceptable salt thereof.

Loading Ampio Pharmaceuticals collaborators
Loading Ampio Pharmaceuticals collaborators